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Summary 
Exposure to amphetamine (AMPH) in vivo produces an enduring enhancement 
(‘sensitization’) in AMPH-stunulated smatal DA release in virro. Experiments were 
conducted to determine whether suiatal DA release evoked by neuronal depolarizauon 
is altered by AMPH pretreatment m a sunilar manner. It was found that AMPH 
pretreatment produced a long-lasting (at least one week) enhancement in sniatal DA 
release evoked by AMPH, KC1 or electrical field stimulation. In contrast, the basal 
rate of DA efflux was not altered by pretteannent coruhtion. A mechanism by which 
a single change in the uuracellular distribution of DA could enhance both AMPH- and 
depolarization-induced DA release is proposed 
In humans chronic amphetatmne (AMPH) abuse frequently results in the development of a 
drug-mduced psychosis (AMPH psychosis) that is clinically similar to paranoid schrzophrema (l-4). 
In nonhuman animals repeated treatment with AMPH produces a progressrve enhancement in the 
motor stimulant effects of AMPH (behavioral sensitization), and this phenomenon IS consulered an 
animal analogue of AMPH psychosis ($6). There has been considerable mterest, therefore, rn the 
neurobiological basis of behavioral sensitizatton. Research on this question has focused on 
mesotelencephalic dopamine (DA) systems, in part because AMPH is thought to produce many of its 
effects on behavior by enhancing dopaminergic acavity, especially DA release (7-9). 
Many neural correlates of behavioral sensitizanon have been reported 11~ the hterature (5), and 
of particular relevance here are reports that behavioral sensitization is accompamed by an 
enhancement in AMPH-stimulated sniatal DA release in virro (10-12) This change in AMPH- 
snmulated DA release can account for a number of features of the behavioral phenomenon. For 
example, both behavioral sensitizahon and an increase in AMPH-stimulated suiatal DA release in 
vrro: (a) can be produced by a single injection of AMPH (12, cf. 13); (b) persist for a very long time 
following the cessation of drug treatment (10.11); and (c) are similarly influenced by how long 
animals are withdrawn from AMPH pretreatment (10). It has been suggested, therefore, that an 
enduring change III the releasability of DA may be responsible for some of the enduring changes in 
behavior produced by past expenence wnh AMPH (5,ll). 
To narrow down the mechanism(s) by which pnor AMPH treatment enhances striatal DA release it is 
important to determine if the effect is specific to AMPH-stimulated DA release, or whether the DA 
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release produced by neuronal depolanzanon is changed m a sn~~lar manner This is because DA 
release stnnulated by AMPH is due to a tierent process than the neuronansrmtter release associated 
with impulse flow and the depolarization of axonal terminals (9) Depolarizanon-mduced DA release 
is thought to occur by Ca*-dependent exocytosis, whereas AMPH-snmulated DA release is thought 
to occur by a Ca++-independent exchange-diffusion process mvolvmg the DA reuptake carrier (9, 
14) To address this quesaon experiments were conducted usmg an rn vitro superfusion technique 
to determine the effects of AMPH pretreatment on endogenous smatal DA release elicited by either 
(a) AMPH, (b) KC1 depolarization; or (c) depolsrizauon by elecmcal field shmulation. 
Methods 
Subjects and Surgrcal Preparahon 
Adult female Holtzman rats (Holtzman Co., M&son, WI) were housed mdtvldually with food 
and water freely available. The colony room was temperature regulated and lights were mamtamed 
on a 14:lO hr hght.dark cycle (lights on at 08:OO hr). Seven to 14 days before the start of an 
experiment animals were ovanectomized under ether anesthesia Ovanectormzed female rats were 
used for the followmg reasons: (a) female rats show more robust behavioral sensmzaoon than do 
males (15. 16); and (b) ovanectomy elnmnates the vananon in smataI DA release associated with 
hormonal fluctuanons across the estrous cycle (17), but has no effect on sensmzanon (16, 18) 
Quannfication of Behavior 
After each pretreatment inJection of AMPH or saline animals were nnmediately replaced mto 
their home cage and behavior quantified by duect visual observation and rating of stereotyped 
behavior. Animals were rated during a 1 mm observation period every 20 mm following the 
mJection, for a total of 3 hr. Overall stereotyped behavior was rated with a scale adapted from 
MacLennan and Mater (19). Individual components of stereotyped behavior (1 e., smffmg, 
repetmve head and hmb movements and oral behaviors) were rated as described by Rebec and Segal 
(20). A dady cumulanve score for each rating scale was calculated by summmg the ratings obtamed 
during each test session. In addition, the total volume of water mgested over 5 hr followmg each 
inJechon was recorded. 
In Vitro DA Release 
One week after the last pretreatment with AMPH each rat was lalled by decapitation, and the 
bram was quickly removed and placed mto ice-cold medmm Coronal sections were obtained using 
a cutting block s~rmlar to that described by Heffner, Hartman and Seiden (21), and after each 
smatum was chopped mto 1 mm3 pteces it was placed mto a superfusion chamber. The superfusion 
chambers and methods have been described previously (22). Bnefly, the superfusion medium 
consisted of a m&tied Krebs-Ringer phosphate buffer with a final compositton of: 120 mM NaCl, 
4.8 mM KCl, 1.25 mM CaCl2 .2H20, 15 mM MgS04, 15 mM phosphonc acid, 0.1% bovme 
serum albumin, 10 mM glucose and pH 7.4 The medunn was oxygenated with 95% 02 * 5% CO2 
for 15 min and shrred continuously throughout the expenment Superfusion chambers were 
mamtamed at 34’C. and medium was pumped through the chambers at 100 @/mm After tissue 
was placed into a superfusion chamber it was left to eqtuhbrate for 65 mm before begmning sample 
collection. Samples were then collected over 5-min mtervals in ice-chdled tubes contaunng 25 pl of 
0.5 N HC104 with dihydroxybenzylamme added as an internal standard. Samples were stored at 
-20” C unhl assayed by high performance liquid chromatography wtth electrochemtcal detecaon, as 
described previously (22) 
The data from each superfusion were exammed by an experienced Judge (J B.B.) who was 
blind to the treatment condraons, and chambers that failed to meet the followmg cntena were not 
considered viable and were excluded from the experiment For a chamber to be considered viable 
(a) shmulated DA release had to be greater than basal DA efflux (i.e., there was not a progressive 
decrement m DA efflux); and (b) at the end of the experiment the tissue had to respond to a 60 mM 
KC1 challenge by an mcrease in DA release (indicaang that the tissue was still viable) Chambers 
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were usually excluded for reasons directly attributable to experimenter error or equipment 
malfunctron, and there was no group bras in the number of chambers excluded. These methods 
were used m all of the following experiments. and procedures specific to each experiment are 
described below. 
Experiment 1: The ettect ot AMPH pretreatment on AMPH-sltmulated striial DA release ln vttro: 
dose-response relations 
Ampherumlne prerreament Animals were either pretreated w-tth 3.0 mg/kg of d-AMPH sulfate 
(1.p.) drssolved m 0.9% saline (weight of the salt) once daly for 6 consecutive days, or left 
undisturbed in then home cage (non-handled). Non-handled controls were used in this experunent 
to mtmmize the stress-induced sensitizanon of dopammergic activity sometimes produced by 
repeated saline mJechons (23,24). 
Supetfuston After the 65 mm equilibration penod (see above) 3 baseline samples were 
collected over 15 mm. At the beginmng of the next interval medium containing d-AMPH was 
mfused for either 5 mm (with 0.5,2.75 and 5.0 PM AMPH), or 2.5 mm (with 10 l.tM AMPH), and 
samples collected for an additional 30 min (all independent groups). Finally, 60 mM KC1 was 
infused for 2 5 mm and one addihonal5min sample was collected. It should be noted that the doses 
of AMPH used here are lust at threshold for evokmg consistent DA release m tins apparatus, 
representmg the extreme far left and nonlinear pornon of the dose-response curve for AMPH-evoked 
striatal DA release (see Fig. 4 in ref. 22). It was hoped that thrs would maximize the probability of 
detecnng an increase m the releasability of DA due to pretreatment condmon. 
Experiment 2: The ettect ot AMPH pretreatment on KCI-evoked DA release 
Amphetanune pretreatment. Ammals received 3 0 mgtkg of d-AMPH or 1.0 ml/kg of 0.9% 
salute once a week for 5 weeks (a total of 5 mlechons). 
Supe@ksron One week after the last inJection of AMPH or sahne stnatal tissue was placed 
into superfusron chambers as described above, except after baseline the hssue was stimulated by 
includmg 25,35 or 45 mM KC1 m the medmm for 5 min (the concenuanon of NaCl was reduced 
propomonately). The DA release evoked by these concentrations of KC1 has been previously shown 
to be Ca* and temperature-dependent (22). 
Electrical stlmulatlon-Induced DA release 
Apparatus The top and bottom of each superfusron chamber was fitted wrth a Ag-AgCl 
electrode (In Vrvo Metric Systems, Healdsburg, CA). The circular surface of the top electrode had a 
cross-secnonal duuneter of 15 mm and the bottom electrode a diameter of 4 0 mm. The electrodes 
were soldered with Ag solder to lead wrres and the solder Joint reinforced wrth a conducnve Ag 
epoxy adhesive (Tra-Con). The electrodes were insulated with teflon heat-shnnk tubmg, except for 
the cross-sectional area of the up, and were separated by 12 mm (which mamtamed a 200 l,tl volume 
m the chambers) Nylon mesh spacers were used to prevent tissue from restmg directly on the 
electrode surface 
Ag-AgC1 electrodes were used rather than platinum, which is frequently used for in vitro 
strmulanon expenments, for several reasons: (a) It has been reported that phMum acts as a catalyst 
for the oxrdanon of neurotransmmer substrates or of glucose, but Ag has mimmal deletenous effects 
on tissue vrabrhty compared to other metals (25-27), (b) Ag apparently does not affect tissue 
metabolism (25), and (c) chlonded electrodes are maximally mert to physrologtcal solutions and 
resistant to electrolyhc processes (25.27) 
The electrical shmtthrs was provided by a Grass S8 snmulator and consrsted of two rectangular 
D.C. pulses that were passed through mdrvldual snmulus isolahon units (Crass Model SIU 478A) 
and m&vldual constant current umts (Crass Model CCUl A). The second pulse was delayed by the 
durahon of the first pulse and its polarity reversed at the constant current unit to create a true biphasrc 
pulse. Brphasic pulses were used to mmrrnize the tissue damage and electrode polarization 
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sometimes associated with the use of monophasic pulses in vitro (28). Current was momtored by 
recording the voltage drop across a resistor located in senes with the chamber. 
Pdot studtes. A series of pilot expernnents were conducted to vahdate the electrical stunulauon 
procedures and to determine suitable stunulus parameters. First, the intensity, pulse durauon and 
pulse frequency were varied to determine parameters that evoked a consistent enhancement m DA 
release. Second, the effect of varying the snmulus frequency (5, 10, 20, 30, 40, or 50 pulse/set, 
[pps]) on DA release was detenmned, while curtent (40 mA) and pulse duration (2 msec) were held 
constant. 
The thud issue addressed in pilot studies was whether the release produced by a highly 
effective samulus was sensitive to calcium and temperature. Wuh electrical stunulation It is possible 
to produce nonselectrve neurotransrmtter release with high mtensity stimulation (29) It is difficult, 
however, to compare samulauon parameters from lab-to-lab because resistance varies greatly wrth 
such thmgs as chamber volume, the density of hSSUC. packing, and the surface area and distance 
between the electrodes. As pomted out by Onego (28, p 1048) it is not possible to know the actual 
shmulatmg current because, “most of the current that flows in the system is short clrcutted through 
the bulk of the hqtud” Therefore, superfusion experiments were conducted as described above, 
except chambers were tested wuh either: (a) normal medium at 34”C, (b) m&urn without ad&tronal 
Ca++ (magnesium was increased to 2.45 mM) and at 34’C, or (c) normal medmm, but at 0°C 
Stimulus parameters that produced a rate of DA release of approximately 200 pg DA/mg ussue/nun 
were used, which consisted of 40 mA, 2 msec pulses applied at 50 pps for a total of 2 mm. 
Experiment 3: The ettect ot AMPH pretreatment on electrical stimulation-evoked DA release 
Amphetamuz pretreatment. Ammals received either an 1 p injecuon of 3.0 mg/Icg of d-AMPH 
sulfate or 1 ml/kg of 0 9% salme once a day for 6 consecutive days An atioonal group was left 
undisturbed in their home cages during this time (nonhandled). Behavtor was momtored only 
following the first and sixth mlecoon, as described above 
Superfusron One week after the last injection superfusion expenments were conducted as 
previously described,, except 20-mm frachons were collected for a total of 3 samples After one 
basehne sample was collected the tissue was stunulated with electrical field ShUIUlatIOn COUSlShng of 
brphaslc rectangular pulses (20 mA, 2 msec duration) applied for 10 set on/l0 set off for 40 nun 
Independent groups of chambers were shmulated at either 5, 10, or 20 pps It should be noted that 
the highest rate of sumulahon used in this expenment (20 pps) was ten tunes lower than used in the 
pilot experiment to detemune Ca++ and temperature dependence (0 8 mCoulombs/sec vs 
8 mCoulombs/sec. respecnvely), and that each chamber was tested with only one frequency. 
Results 
Behavior. 
All of the AMPH pretreatment regimens produced a slmtlar and significant enhancement m the 
motor stunulant effects of AMPH (1 e , behavioral sensitization) Data are shown only for Exp. 2 to 
illustrate typical behavioral effects (also see 15, 18, 30). Fig 1 shows that repeated AMPH 
treatment produced a progressive and sigmficant enhancement m the ratmgs of overall stereotypy, 
stuffing and repenuve head movements, and m the amount of water ingested There was no effect of 
repeated AMPH treatment on oral stereotypies (data not shown), consistent with previous reports 
(20, 31) 
Experiment 1: The effect of AMPH pretreatment on AMPH-stimulated striatal DA release In vitro. 
Fig 2 shows that the inclusion of AMPH in the superfusion medium enhanced endogenous 
smatal DA release above basal levels of DA efflux in all groups (1 e , all means are sigmficantly 
greater than 0). There was no effect of AMPH pretreatment on AMPH-stimulated DA release 
evoked by infusion of 0 5 pM or 2 75 pM AMPH for 5 nun However, mfusron of 5 PM AMPH 
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for 5 min. or 10 @4 for 2.5 mm, produced a significantly greater increase in DA release m the 
AMPH pretreated group than in the control group (Fig. 2). 
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Fig. L. The effect of 
repeated AMPH treatment 
on stereotypy ratings and 
drinking behavior. The 
~&ols represent the mean 
(S.E.M ; N = 38) values 
@er each of 5 injections of 
3 0 mglkg of AMPH given 
at weekly intervals There 
was a sigmficant increase in 
the ratings of overall 
stereotypy (A), sniffling 
(B), and head and limb 
movments (C; comparison 
of first and last mJection, 
Wilcoxon tests, p’s c 
0 001) The increase in 
water consumption (ml) 
was also significant (0, 
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phll AMPH- 0.5 2.75 5 10 
Minutes- 5 5 5 2.5 
lQ&. The e#ect of pretreatment with AMPH 
on AMPH-stimulated endogenous striatal DA 
release in vuro. The bars represent the mean 
(+S.E.M.) change (A) in DA efflux from 
baseline. expressed rn pg DAlmg tlssuelmin 
(i e.. a value of zero represents no change from 
baseline) The groups drd not differ in the basal 
rate of DA efflux, which averaged 23.97ti.97 
pglmglmm across all groups. There was no 
eflect of pretreatment condition on DA release 
evoked by either 0 5 or 2.72 @I AMPH. 
However, there was a greater increase in DA 
e$lux from the AMPH-pretreated group when 
the tissue was challenged with 5 pM of AMPH 
for 5 min or 10 pM for 25 min (planned I -taded 
t-tests, t[8]=3 15, **p=o 007. t[7]=2.22, 
*p=O 031. respectively) 
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Experiment 2: The ettect ot AMPH pretreatment on KCI-evoked strlatal DA release. 
Fig. 3 shows that the addmon of 25 to 45 mM KC1 to the superfuslon medmm increased 
endogenous DA release above the basal level of DA efflux in all groups (i.e., all means are greater 
than 0). More Importantly, KC1 produced a greater increase in DA release m the AMPH-pretreated 
group than in the control group. The 2-way analysis of variance resulted in a significant main effect 
and no significant interaction, but mspecuon of Fig. 3 reveals a tendency for a larger effect of 
pretreatment condition with the higher concentrations of KC1 
- Amph-pretreated 
25 35 45 
KCI (mM) 
m The qJect of pretreatment with AMPH 
(solid crrcles) on endogenous smatal DA release 
evoked by 25,35 or 45 mM KC1 in vrtro The 
symbols represent the mean (IS EM ) change 
(A) in DA e#lux from baselrne, expressed m pg 
DAlmg trssuelmin. There were no group 
differences in the basal rate of DA e$lux, which 
averaged 18 22fI 71 pglmglmin across all 
groups However, a 2-way analysis of variance 
on the change in DA eflux produced by KC1 
resulted in a srgtuficant effect of pretreatment 
condltlon (F[I, 321 = 4 17, p = 0 046), a 
srgnrficant fleet of KC1 concentration (F[2,32] 
= 6 99, p = 0 003) but no slgnrjicant mteractlon 
Electdcal stknulation-induced DA release: Pilot experiments. 
A 40 mA, 2 msec shmulus apphed for 2 mm &d not produce a sigmficant increase in DA efflux at 
frequencies below 20 pps. As the stimulus frequency was increased above 20 pps DA efflux 
increased to an average of approxnnately 200 pg DA/mg &sue/mm at 50 pps. The mcrease m DA 
efflux produced by the highest intensity stimulus tested (40 mA, 2 msec, 50 pps) was reduced by 
74% if Ca++ was excluded from the medmm, and this shmulus was completely ineffective m 
inducing DA release when the chambers were kept at 0°C 
Experlment 3: The effect of AMPH pretreatment on electrical stimulation-evoked DA release. 
Elecmcal shmulaaon sign&candy enhanced DA release above the basal levels of DA efflux 1~1 
all groups (1 e., all means are greater than 0; Fig 4) There was no tiference between the salme- 
pretreated and nonhandled control groups. and therefore they were pooled for comparison with the 
AMPH-pretreated group. Elecmcal snmulaaon evoked a greater change m DA release in the AMPH- 
pretreated group than in the control group, as mQcated by a significant mam effect of pretreatment 
condition (Zway ANOVA) The ANOVA &d not result m a signScant uneraction, but mspecaon of 
Fig. 4 reveals a tendency for a greater effect at the highest stimulus frequency 
Discussion 
The AMPH pretreatment regimens used in the present expenments produced behavioral 
sensmzanon, as expected from previous studies (30,32-34,5 for review). Furthermore, behavioral 
sensitizaaon was accompamed by a dose-related enhancement m AMPH-stimulated smatal DA 
release in vitro, which confirms and extends previous studies (10-12). Most unportantly, AMPH 
pretreatment also produced an endurmg enhancement m the Ca*-dependent release of DA evoked by 
high KC1 or elecmcal field shmulation. These latter stu&es estabhsh that senntizatron-related 
changes in smatal DA release are nof unique to AMPH-samulated DA release 
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FREQUENCY (PPS) 
&& Tk effect of pretreatment with AMPH 
(solid symbols) on endogenous sm*atal DA release 
in vitro evoked by electrical field stimulation 
applted at 5, 10 or 20 pulseslsec (PPS). The 
symbols represent tk mean (Itli.E.iI4.J change (A) 
ln DA efflux from baseline, expressed in pg 
DAlmg tissuelmin. There were no group 
differences in tk basal rate of DA eflux, which 
averaged 16.5321.06 pglmglmln across all 
groups. However, a 2-way analysis of variance 
on tk change in DA &7ux produced by elecm’cal 
stimulatron resulted rn a stgntficant effect of 
pretreatment conditron (F[I, 821 = 4.24, p = 
0.04), a significant effect of stimulus frequency 
(F[2, 821 = 8 95, p c 0.001) but no significant 
mteractwn 
However, not all challenge doses of AMPH were effective. Smatal tissue from AMPH 
pretreated animals showed a greater elevation m DA release than tissue from control ammals when 
challenged with 5 @A AMPH for 5 min or 10 PM for 2.5 min, but not when challenged ~th lower 
doses (0.5 and 2 75 PM). In companson, Robmson & Becker (11) reported sensiazahon-related 
changes m smatal DA release when 1 w of AMF’H was infused contmuously for 10 mm. 
Smularly, using an mcubahon procedure, Kolta et al. (10) found that both 1@4 and 10 W AMPH 
were effective when applied for 15 min, although the 10 PM challenge more clearly differentiated 
the AMPH pretreated and control groups than &d the 1 PM challenge. In one study, a much higher 
dose of AMPH (1 mM) was delivered as a bnef pulse, which quickly washed out of the chamber, 
and this also resulted in a senntizatlon-related enhancement in smatal DA release (12). Taken 
together, the avsulable evidence suggests that the ablhty of an zn vitro AMPH challenge to reveal 
sensitlzatlon-related changes m stnatal DA release 1s mfluenced by the duratton and concentrauon of 
the AMPH challenge. The effects of AMPH pretreatment on AMPH-snmulated DA release may be 
seen under some experimental con&nons, but not others 
The effect of AMPH pretreatment on the Ca *-dependent DA release evoked by either lugh 
KC1 or elecmcal field sumulatlon reported here appears to be hscrepant with a previous study from 
this laboratory, m which it was found that KCl-evoked striatal DA release was not enhanced in 
sensitized rats (11). The most probable explanation for this is an order effect. In the Robinson and 
Becker (11) study striatal tissue was always exposed first to AMF’H, and then to KCI. Therefore, 
AMPH may have depleted the amount of DA avdable for subsequent KCl-stimulated DA release It 
1s thought, for example, that AMPH &splaces bound DA from storage pools (14), which would 
leave less DA available for subsequent release by KCl. There was no such order effect in the present 
expenments. because the data are based only on the lnihal response to either AMPH, KC1 or 
elecmcal stunulahon. 
As mennoned in the mrroduction, the process thought to metite AMPH-smnulated DA release 
(Ca++-Independent, tamer-medated exchange-diffusion) 1s very hfferent than that thought to 
me&ate DA release produced by depolanzaaon of axonal terrmnals (Ca*-dependent exocytons). 
Therefore, the observanon that sensmzation 1s accompanied by an enhancement of not only AMPH- 
stunulated DA release, but also of KC1 and elecmcal shmulahon-evoked DA release, has important 
imphcanons for hypotheses regan%ng the neuroblolo@cal basis of the enhancement m DA release. 
Either the senslhzation-related enhancement in DA release 1s due to more than one mechanum, for 
example, one responsible for the enhancement m AMPH-samulated DA release and another for the 
enhancement in depohmzation-induced DA release, or, a mechanism common to both AlWH and 
depolarizahon-induced DA release is mvolved. 
There are many neuronal adaptanons that could lead to increased DA release, but most have 
hfficulty accounting for changes in both depolanzanon-mduced DA release and AMPH-stunulated 
DA release For example, It has been suggested that the sensihzation-related enhancement m DA 
2454 Sensitization to Amphetamine Vol. 42, No. 24, 1988 
release and AMPH-induced behavior may be due to a subsensmvny of DA autoreceptors (35-37). 
But AMPH-strmulated DA release does not seem to be modulated by DA autoreceptors (38), and 
therefore, it is not clear how a change m DA autoreceptors could account for the sensitizanon-related 
enhancement in AMPH-shmulated DA release and AMPH-evoked behavior. Smularly, a role for 
Ca++ in AMPH sensmzauon is suggested by a report of mcreased smatal calmoduhn levels m AMPH 
pretreated rats (39) But AMPH-smnulated DA release is not Ca++--dependent, and therefore, it 1s 
not obvious how changes in Ca* mflux or a Ca++-bm&ng protem could account for changes m 
AMPH-stimulated DA release and AMPH-ehcrted behavror 
release could be due to an alteration in the reuptake carrier. 
A change m AMPH-stimulated DA 
But the Ca*-dependent release produced 
by KC1 IS not affected by the presence of the DA reuptake blocker nonufensme, and this suggests 
that depolanzanon-induced release occurs mdependently of the uptake mechamsm (40). Therefore, 
changes m the uptake mechamsm could me&ate the enhancement m AMPH-stimulated release, but 
presumably not the effects of AMPH pretreatment on Ca*-dependent DA release 
The idea that a common mechamsm mediates the enhancement m both AMPH-stimulated and 
depolarization-mduced striatal DA release should be given serious consideraaon, not only because rt 
IS more parsunomous, but because it could also help explam the mterchangeabrhty of AMPH and 
stress m producing sensmzauon. Animals sensitized to AMPH exhrbit enhanced behavtoral and 
neurochemical responses to subsequent swss (23,41,42), and pnor stress enhances the behavroral 
and neurochemical responses to a subsequent AMPH challenge (23,24,41,43-45). 
How could a smgle change alter the releasabthty of DA to both AMPH and depolanzanon? It 
1s not due to Just an mcrease in the total amount of presynapnc DA, because AMPH pretreatment 
does not alter mesotelencephahc DA concentratrons (15, 18, 46-48, 5 for revrew). But it is 
important to consider that DA is probably located in at least 3 tiferent compartments, or ‘pools’, 
and release occurs more retiy from some pools than from others (9,49-52). A free cytoplasnuc 
pool is thought to contain newly synthesized DA, largely because tyrosme hydroxylase and dopa- 
decarboxylase are not associated with synaptic vesicles (52) AMPH seems to release DA selecnvely 
from this pool. Metabolically older neurotransmitter is presumably bound within storage 
compartments, for protectron from metabohsm, until it is released by a Ca++-dependent release 
process. Bound pools of DA rmght correspond to vesrcular stores, and there are probably two pools 
of bound DA; one that IS rea&ly releasable by the arrival of an acuon potenhal at the nerve termmal 
(‘releasable bound DA’) and another that is not (‘macave bound DA’) The drfference between these 
two bound pools may be that releasable bound DA is simply closer to the neuronal membrane than 
the mactrve pool, and thus has greater access to release sttes (50) A redrsmbution of DA among 
these pools, wtth no change m total DA, could lead to an increase rn both AMPH and depolan.zahon- 
induced DA release m the followmg way 
A transfer of DA from the machve bound pool mto the releasable bound pool would obviously 
result m more DA redly avarlable for release upon depolanzanon of the termmal. There would be 
no alteranon m the size of the cytoplasmrc pool m the absence of an AMPH challenge After AlWH 
is taken up mto a DA terminal, however, it not only mduces DA release mto the extracellular space 
by exchange-diffusion, but it also dsplaces bound DA into the cytoplasm (9, 14). Thus, if AMPH 
pretreatment enhanced the srze of the releasable bound pool, for example, by a physical translocatron 
of vesicles closer to release sttes on the presynapttc membrane, then presumably they would also be 
closer to reuptake sites on the presynaptic membrane. AMPH that had lust entered the cytoplasm 
would, therefore, have access to an augmented releasable bound pool and a greater opportumty to 
&splace DA from this augmented releasable bound pool This would increase the amount of DA m 
the cytoplasnuc pool, resultmg m more DA being reruhly available for exchange&ffusron as AMPH 
entered the cell. In conclusion, it 1s suggested that a single change - an increase in the srze of the 
releasable bound pool of DA - could result m an enhancement of both AMPH and depolanzation- 
induced DA release 
This hypotheses 1s speculahve, and further research is requrred to determme the neurobiologtcal 
basis of the enhancement in DA release produced by AMPH pretreatment Nevertheless, the present 
study suggests that explorahon of presynaphc mechamsms that conconutantly regulate both uptake 
tamer-mediated chemical release and tmpulse-related Ca++-dependent release may provide a 
Vol. 42, No. 24, 1988 Sensitization to Amphetamine 2455 
prormsing strategy for increasmg our understanding of the biological basis of behavioral 
sensmzanon 
In summary, it was shown that the behavioral sensitization produced by repeated intermittent 
injections of AMPH is accompamed by a persistent enhancement m AMPH-stimulated endogenous 
striatal DA release, and in Ca++-dependent DA release evoked by high KC1 or electrical stimulanon 
in vitro. These results support the hypothesis that an enhancement in smatal DA release may be at 
least partly responsible for the behavioral sensitization seen in AMPH-pretreated animals (5, 1 l), 
and perhaps even the hypersensmvny to the psychotogenic effects of AMPH seen in former AMPH 
addicts (53-55). Of course, tlus does not exclude the possibility that changes m other neural systems 
are also involved (eg. 5,23.41.45,56). The observation that sensitization-related changes III DA 
release are not unique to AMPH-stimulated DA release is also consistent with the hypothesis that 
behavioral sensitization is not unique to the psychopharmacology of AMPH (56). 
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